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Adam Hurlstone and Donald M. Black
Cancer of the prostate gland is the highest unavoidable
cause of cancer mortality in men. The recent
identification and characterisation of genes specifically
expressed in prostate cancer helps us to understand its
molecular basis and should offer new therapeutic
avenues to combat this disease.
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Prostate cancer (prostatic adenocarcinoma) is the most fre-
quently diagnosed malignancy in men in many of the
world’s developed countries, and accounts for 10% of
cancer-related deaths in men. An increase in the histologi-
cal incidence of prostate cancer has been reported recently
in many countries in the western world. The greatest pro-
portion of this increase is due to more sensitive and earlier
detection of the disease, largely attributable to the intro-
duction of testing for the presence of a prostate cancer-
associated protein in serum. However, a more alarming
upward trend in age-adjusted mortality rates from prostate
cancer reveals a genuine increase in the incidence of
aggressive cancers [1].
The majority of prostate cancer is diagnosed incidentally
as benign prostatic hyperplasia, which affects approxi-
mately 80% of males by the age of 80 years. It has been
estimated that about one in six prostate glands resected to
alleviate this condition contains areas of carcinoma. Addi-
tionally, post-mortem examinations indicate that 10–30%
of all men older than 50 years harbour a ‘silent’ micro-
scopic form of prostate cancer. The majority of latent car-
cinomas follow an indolent course, but a small proportion
become aggressive and these often prove fatal [2].
Localised prostate cancer is potentially curable by radical
prostatectomy or radiotherapy. However, the majority of
prostate cancer patients present with disseminated
disease. Ablation of male hormones — androgens —is the
key form of treatment for these individuals, as the cancer
cells initially depend on hormone supply for growth. This
measure is largely palliative, though, and most patients
show disease progression between 12 and 18 months after
this treatment begins, as the prostate tumour cells
progress to androgen-independent growth. Regrettably,
there is no effective remedy for hormone-resistant disease,
and survival time is typically 2–3 years from the time of
diagnosis of metastatic disease [3].
The increased incidence of prostate cancer and a burgeon-
ing older population make it imperative that reliable prog-
nostic indicators become available to clinicians to allow
the early detection of that subset of latent tumours that is
likely to become aggressive. In turn, this requires that the
cellular and molecular events underlying tumour progres-
sion and recurrence be fully understood.
Markers of prostate cancer
A number of markers associated with the prostate gland
have been identified to date including prostate-specific
antigen (PSA) [4], prostate carcinoma-associated glycopro-
tein complex (PAC) [5], prostatic acid phosphatase (PAP),
prostate mucin antigen (PMA) [6], and prostate-specific
membrane antigen (PSM) [7]; only a subset of these
markers are elevated in or specifically associated with
prostate cancer, however. A number of studies have
focused on PSA, a serine protease that liquefies seminal
coagulum. PSA is secreted by luminal epithelial cells of
prostate glands and can be detected in the bloodstream.
Expression of PSA is higher in normal than in malignant
prostate cells, and even falls in recurrent hormone-resis-
tant disease. However, the vast increase in the number of
PSA-producing cells due to the cancer-induced enlarge-
ment of the prostate gland results in the elevation of PSA
protein levels in the serum of prostate cancer patients.
Measurements of serum levels of PSA are therefore used
clinically to provide an indication of tumour burden,
metastatic involvement, and response to surgery, radio-
therapy and androgen ablation. PSA levels fail to discrimi-
nate accurately, however, between indolent and aggressive
cancers, benign prostatic hyperplasia, prostatitis and other
non-malignant disorders; thus, PSA measurements alone
cannot be used diagnostically or prognostically. 
By analysing PSA or PSM messenger RNA (mRNA)
expression by the highly sensitive reverse-transcription-
coupled polymerase chain reaction (RT–PCR) approach,
it is possible to detect the presence of a single prostate
cancer cell among a million non-prostatic cells [9]. PCR
analysis can therefore be used to detect prostate cancer
micrometastases distributed by the bloodstream [8], thus
providing an early indication of prostate cancer progres-
sion. PSM may be a more accurate and sensitive indicator
of the metastatic progression of prostate cancer than PSA,
because expression of this marker is elevated in tumour
cells, hormone-resistant cancer cells, and bony metastases
[10], unlike PSA.
Two recent papers herald important advances in our
ability to detect and possibly intervene in the progress of
prostate cancer. In a paper from Owen Witte’s laboratory,
Reiter et al. [11] document the discovery of a prostate
cancer-associated cell surface antigen, prostate stem cell
antigen (PSCA), which was overexpressed in about 90% of
the prostate cancer specimens they examined. In the other
paper, Paul Fisher’s group have continued their analysis of
the prostate cancer tumour-inducing gene 1 (PTI-1),
demonstrating the dominant transforming potential of the
gene and showing that expression of antisense PTI-1 RNA
reverses the tumorigenicity of an experimentally trans-
formed cell line, while inhibiting the growth of a number
of carcinoma-derived cell lines [12]. 
Prostate stem cell antigen, PSCA
PSCA is a previously unidentified molecule related to
stem cell antigen 2 (Sca-2), a member of the Thy-1/Ly-6
superfamily of glycosylphosphatidylinositol (GPI)-
anchored cell surface antigens [11]. The authors demon-
strated, using mRNA in situ hybridisation, that the gene
encoding PSCA was overexpressed in 90% of prostate
cancers. These included high-grade intraepithelial neopla-
sia and hormone-resistant cancers. Overexpression of
PSCA may result from gene amplification because the
PSCA gene maps to chromosomal region 8q24.2, which
has been reported to be a region of allelic gain and ampli-
fication in a majority of advanced and recurrent prostate
cancers. Reiter et al. [11] confirm that PSCA is GPI-
anchored at the cell surface, and also show that PSCA is
expressed only in a subset of basal epithelial cells in
normal prostate gland. The authors conclude that this
finding supports other data suggesting that prostate
cancers arise from the transformation of basal cells, which
are believed to be the progenitors of the terminally differ-
entiated secretory cells in the prostate gland. Finally,
although no data are available as yet to support this, by
analogy with Sca-2, the authors propose that PSCA may
play a role in the survival or self-renewal of the basal
epithelial cells.
The association between elevated PSCA expression and
prostate tumorigenesis, coupled with sustained expression
of this molecule even in recurrent hormone-resistant
disease, promotes the use of this marker in disease detec-
tion, and possibly in prognosis and treatment. Serum
detection of PSCA protein may be possible if, like other
GPI-anchored proteins, a fraction of the PSCA molecules
are secreted. Alternatively, RT–PCR detection of PSCA
expression could be used, as with PSM, to detect disease
spread by the bloodstream. Also, the cell surface expres-
sion of PSCA or PSM could allow for the immunological
detection of metastases using specific antibodies raised
against these proteins. In fact, a clinical study using an
antibody raised against PSM is currently under way [13]. If
these studies prove successful, detection of prostate-
cancer-associated molecules in the blood of patients would
clearly be of immense benefit for the clinical management
of prostate cancer. If coupled to radioisotopes or cytotoxic
agents, antibodies specific to these markers could even
selectively kill cancer cells. Identification of the natural
ligands for both PSM and PSCA might allow small pep-
tides to be designed that could selectively bind cancer
cells, substituting for antibody-mediated therapies and
avoiding associated problems with immunological attenua-
tion. Finally, the restricted expression of PSCA to prostate
cancer tissue and its expression on the surface of cells
advance its candidacy as a possible prostate cancer
immunogen for anti-cancer vaccination therapy.
Prostate cancer tumour-inducing gene, PTI-1
Expression of the PTI-1 gene appears to be even more
restricted to prostate cancer cells than that of either PMS or
PSCA: again, RT–PCR was used to detect the expression
of the PTI-1 gene in the blood of prostate cancer patients
[14]. The PTI-1 gene was cloned by a complex experimen-
tal strategy. This involved transferring DNA from a
metastatic prostate carcinoma-derived cell line into rat
embryo fibroblasts, followed by the injection of these cells
into ‘nude’ mice — mice that lack T cells and therefore
cannot elicit an immune response — thereby generating
tumours. RNA from the tumours was then characterised
using differential display, a PCR-based technique for com-
paring RNA profiles between different cell populations, in
order to identify genes that had increased expression in the
tumours, one of which was PTI-1 [15].
The PTI-1 mRNA has a most peculiar structure. It com-
prises a 630 bp 5′-untranslated region, with very high
similarity (about 90% identity) to the Mycoplasma hyop-
neumoniae 23S ribosomal RNA, fused to a sequence
which encodes a mutated and truncated version of
human translation elongation factor-1α (EF-1α). It
appears therefore that the PTI-1 gene arose by fusion
between these two genes, followed by subsequent diver-
gence from the ancestral sequences. It is not clear if the
PTI-1 gene is present in the human genome as a single
genetic locus, or if it is a fusion product specifically gen-
erated in cancer cells by chromosomal translocation,
deletion or insertion. The region of PTI-1 that is homolo-
gous to the prokaryotic 23S ribosomal RNA has been
confirmed to be present in humans by PCR analysis of
genomic DNA [14]: direct confirmation by Southern
hybridisation analysis of genomic DNA using this region
of the PTI-1 gene as a probe and by cloning and chromo-
somally mapping the PTI-1 locus would help eradicate
any suspicions that this gene might be in some way arte-
factual. This information would also enable us to deter-
mine whether the PTI-1 locus is linked to familial
prostate cancer, which is believed to be responsible for
about 10% of the cases of the disease. The PTI-1 mRNA
has been detected only in carcinoma cell lines (not exclu-
sively prostatic, but also breast and colon cancer cell
lines), and in about 90% of prostate cancers. Importantly,
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the PTI-1 gene is not expressed in normal prostate
glands or in benign prostatic hyperplasia [15]. 
In their recent paper [12], the Fisher group provide further
cogent evidence for the dominant transforming ability of
PTI-1, thus substantiating it as one of very few oncogenes
identified to date — including c-ERBB-2/NEU/HER-2, 
c-Ki-RAS, c-MET, and c-MYC — that are implicated in
prostate tumorigenesis. From studies largely of EF-1α
homologues in bacteria and yeast, EF-1α is believed to
ensure proper codon–anticodon binding interactions
between mRNAs and transfer RNAs (tRNAs) at the tRNA
acceptor site of the ribosome [16]. Mutations in EF-1α
would be likely to affect its proofreading ability and could
therefore promote the synthesis of mutant proteins, which
themselves may possess transforming ability. This theory
for the oncogenic potential of EF-1α has been termed the
‘translational infidelity hypothesis’ [15].
Altered protein translation has previously been associated
with cellular transformation. Enhanced expression of EF-
1α has been demonstrated in tumours of the pancreas,
colon, breast, lung, and stomach when compared with that
in adjacent normal tissues [17]. Overexpression of the
wild-type form of the eukaryotic translation initiation
factor eIF-4E, the mRNA cap-binding subunit of eIF-4F,
or a constitutively active form of the eIF-2α initiation
factor promotes fibroblast transformation. The work of the
Fisher laboratory on PTI-1 further strengthens the pro-
posed link between translation and transformation.
The ability of antisense PTI-1 RNA to revert the malig-
nant phenotype of PTI-1-transformed cells highlights the
potential for this mode of oncogene inactivation as an anti-
tumour gene therapy, should mechanisms of cell targeting
and gene transfer become practicable. Alternatively, it may
be possible to engineer small antisense oligonucleotides to
inhibit PTI-1 expression. These could be delivered sys-
temically and would diffuse throughout tissue spaces
finding their way even to metastases. Alternatively, it
might be possible to exploit the tissue-specific expression
of molecules such as PMS, PSA, PSCA and PTI-1 in anti-
prostate cancer gene therapy approaches: promoters of the
genes encoding these products could be used to drive the
expression of suicide genes (such as the thymidine kinase
gene of herpes simplex virus) specifically within prostate
cancer cells. In fact, as you read this, you can be quite sure
that these promoters have already been inserted into
someone’s favourite ‘gene therapy vector’, and that pilot
studies are currently under way in a ‘pet’ model system to
determine the efficacy of such an approach.
The demonstration that the PMS, PSCA and PTI-1 genes
are expressed in androgen-insensitive cells, unlike PSA
which is expressed in an androgen-dependent manner,
suggests that therapies intervening with the function of
these genes could potentially even be used to tackle
recurrent disease, the Gordian knot waiting to be cut. 
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